CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

HR Notices From May 14

View Comments
(credit: istock) Technology Report
Read More

Henry Ford Hospital Names Director of New Structural Heart Disease Program:  William W. O’Neill, M.D., has been appointed medical director of the new Center for Structural Heart Disease at Henry Ford Hospital. He will begin his new position on July 31. Dr. O’Neill is an internationally recognized leader in interventional cardiology and research in new techniques to diagnose and treat heart disease. He pioneered the use of angioplasty for treatment of heart attacks, which is now the mainstay therapy throughout the world.  He has been working on new catheter-based treatments of structural heart disease, and performed the first aortic valve replacement through a catheter in the U.S. in 2005. A leader in academic and teaching hospitals for nearly 30 years, and to date, an author of more than 300 hundred peer-reviewed articles and abstracts published in medical literature, Dr. O’Neill has written multiple book chapters, and edited one of the first textbooks in the field of interventional cardiologists. He was a founding member of the American Board of Internal Medicine interventional cardiology board, which certifies all interventional cardiologists. He is the former executive dean for Research, Research Training and Innovative Medicine, and CEO for Research at University of Miami Miller School of Medicine.  Previous positions include corporate chief of Cardiology at William Beaumont Hospital, as well as director of the cardiac catheterization laboratory and associate professor of medicine at the University of Michigan Hospital. A graduate of Wayne State University School of Medicine, where he was a resident, Dr. O’Neill completed a cardiology fellowship at the University of Michigan Hospital.

C/D/H Promotes Eric Inch To Lead Consultant: C/D/H announced that Eric Inch has taken a broadened leadership role in the company as Unified Communications Lead Consultant. As Lead Consultant, Inch will lead and grow the firm’s unified communications service offerings, including Microsoft Lync, Exchange, Office 365, and Active Directory. Inch will be responsible for directing staffing, work flow, technical quality and other aspects of client projects. Inch holds various certifications with Microsoft, Cisco, and security. He is an expert at planning and implementing Microsoft Lync, Exchange and unified messaging, cloud services, directory services, and security. He holds a Master of Science in Administration from Central Michigan University. Inch joined C/D/H as a consultant in 2008.  A native of Elk Rapids, Inch now resides in Grand Rapids. C/D/H is a technology consulting with more than 20 years of service to clients across Michigan. The firm has offices in Royal Oak and Grand Rapids, from which it provides clients with consulting services in collaboration, infrastructure, and project management.  C/D/H is certified as a Microsoft Gold Partner, a VMware Enterprise Partner and also has earned top levels of certification with Novell, Citrix and Cisco Systems.  For more information, visit www.cdh.com.

Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs: Ann Arbor-based Synthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today the appointment of Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs. In this position, Dr. Reed will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. Dr. Reed brings over 25 years of experience, in medical practice and in the biotechnology/pharmaceutical sector, including six years with Clinical Data, Inc., a publicly-traded biopharmaceutical company which was acquired by Forest Laboratories, Inc. Most recently, Dr. Reed served as Chief Medical Officer at Clinical Data, Inc. from 2005 through 2011, after the company merged with Genaissance Pharmaceuticals, Inc., where she had served as Vice President, Medical Affairs since 2003. During her tenure at Clinical Data, Inc., Dr. Reed was responsible for the design and management of two successful consecutive Phase III clinical trials for Viibryd, which is used in the treatment of major depressive disorder in adults. These efforts led to the approval of Viibryd in January 2011 by the U.S. Food and Drug Administration. Prior to this time, Dr. Reed served as Associate Medical Director in Pulmonary Medical Research at Bayer Pharmaceuticals, Inc. Previously, she was the Associate Director, Section of Pulmonary and Critical Care Medicine at the Hospital of St. Raphael and directed its Medical Intensive Care Unit. Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial hypertension, relapsing-remitting multiple sclerosis, cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

View Comments
blog comments powered by Disqus